Reuters logo
BRIEF-Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial
February 15, 2017 / 2:27 PM / 7 months ago

BRIEF-Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial

Feb 15 (Reuters) - Tapimmune Inc :

* Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial after favorable DSMB safety review

* Tapimmune Inc - will be enrolling remaining patients in trial at 12 clinical centers in U.S. with enrollment completion targeted for end of 2017

* Tapimmune Inc- have two additional phase 2 trials now enrolling or about to enroll ovarian and triple-negative breast cancer patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below